Çiğdem KADER, Ayşe ERBAY, Ali RIZA ERBAY, Hüseyin EDE

Drug interaction of boceprevir and amlodipine in a patient with hepatitis C: A cardiovascular follow-up

Boceprevir, Hepatit C virüs (HCV) enfeksiyonunun tedavisinde peginterferon ve ribavirin ile kombine edilerek kullanılan NS3/4A HCV proteaz inhibitörüdür. Boceprevir, büyük çoğunlukla sitokrom P450 ilişkili oksidasyon ve sitozolik aldo-keto redüktaz ile ketoredüksiyon yoluyla metabolize olur. Amlodipin hipertansiyonu olan hastaların tedavisinde kullanılmaktadır ve amlodipin de sitokrom P450 yoluyla metabolize olur. Bu yazıda, boceprevir ve amlodipin kronik HCV enfeksiyonu olan bir hastadaki etkileşimini ve bu hastanın ekokardiyografik ve elektrokardiyografik takip sonuçlarını sunduk

Hepatit C virüs enfeksiyonu olan hastada boceprevir ve amlodipin ilaç etkileşimi: Kardiyovasküler Takip

Boceprevir is a NS3/4A hepatitis C virus (HCV) protease inhibitor, used in combination with peginterferon and ribavirin to treat HCV. Boceprevir undergoes extensive metabolism via cytochrome P450-mediated oxidation and ketoreduction by cytosolic aldo-keto reductases. Amlodipine has been used for the treatment of patients with hypertension and also metabolised through cytochrome P450 pathway. Here, we presented a case of boceprevir and amlodipine interaction in a patient with chronic HCV and her echocardiography and electrocardiographic follow-up results. J Microbiol Infect Dis 2015;5(1): 32-35

___

Merck & Co Inc. Package insert: Victrelis (boceprevir) cap- sules. Available at: http://www.merck.com/product/usa/pi_ circulars/v/victrelis/victrelis_pi.pdf Accessed 16 March 2014.
Ghosal A, Yuan Y, Tong W, et al. and Alton KB Characteriza- tion of human liver enzymes involved in the biotransforma- tion of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011;39:510-521.
Wilby KJ, Greanya ED, Ford JA, et al. A review of drug interac- tions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012;11:179-185.
Hackam DG, Khan NA, Hemmelgarn BR, et al. The 2010 Ca- nadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Can J Cardiol. 2010;26:249-258.
Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a Euro- pean Society of Hypertension Task Force document. J Hy- pertens. 2009;27:2121-2158.
Henneman A, Thornby KA. Risk of hypotension with concomi- tant use of calcium-channel blockers and macrolide antibiot- ics. Am J Health Syst Pharm. 2012;69:1038-1043.
Tungol A.et al. Formulary Management of the Protease Inhibi- tors Boceprevir
and Telaprevir for Chronic Hepatitis C VirusJournal of Managed Care Pharmacy. 2011;17:685-694.
U.S. Food and Drug Administration. FDA news release. FDA approves Victrelis for hepatitis C. May 13, 2011. Available at : http://www.fda.gov/NewsEvents/Newsroom/PressAn- nouncements/ucm255390.htm Accessed 15 March 2014.
Victrelis (boceprevir) capsules. Merck. May 2011. Avail- able at: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2011/202258lbl.pdf Accessed 15 March 2014.
Merck & Co Inc. Package insert: Victrelis (boceprevir) cap- sules. Available
at: http://www.merck.com/product/usa/pi_circulars/v/victrelis/vic- trelis_pi.pdf
Accessed 16 March 2014.
Tóth K. PIANIST Investigators. Antihypertensive Efficacy of Triple Combination Perindopril/Indapamide Plus Amlodipine in High-Risk Hypertensives: Results of the PIANIST Study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyper- tensive patients). Am J Cardiovasc Drugs. 2014;14:137-145.
J Bramlage P, Zemmrich C, Gansz A, et al. Daytime sys- tolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with un- controlled essential hypertension (SEVICONTROL-2).Clin Hypertens (Greenwich). 2014;16:41-46.
Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel block- er-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;18;310:2544-2553.
Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug- drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacoki- net. 2013;52:815-831.